@article{3185897,
    title = "Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool
that predicts 4CMenB strain coverage worldwide",
    author = "Muzzi, Alessandro and Brozzi, Alessandro and Serino, Laura and Bodini, and Margherita and Abad, Raquel and Caugant, Dominique and Comanducci, and Maurizio and Lemos, Ana Paula and Gorla, Maria Cecilia and Krizova, and Pavla and Mikula, Claudia and Mulhall, Robert and Nissen, Michael and and Nohynek, Hanna and Simoes, Maria Joao and Skoczynska, Anna and and Stefanelli, Paola and Taha, Muhamed-Kheir and Toropainen, Maija and and Tzanakaki, Georgina and Vadivelu-Pechai, Kumaran and Watson, Philip and and Vazquez, Julio A. and Rajam, Gowrisankar and Rappuoli, Rino and Borrow, and Ray and Medini, Duccio",
    journal = "Vaccine",
    year = "2019",
    volume = "37",
    number = "7",
    pages = "991-1000",
    publisher = "Elsevier Sci Ltd, Exeter, United Kingdom",
    issn = "0264-410X",
    doi = "10.1016/j.vaccine.2018.12.061",
    keywords = "Neisseria meningitidis serogroup B; 4CMenB vaccine; Strain coverage;
gMATS; Genotyping",
    abstract = "Background: The Meningococcal Antigen Typing System (MATS) was developed
to identify meningococcus group B strains with a high likelihood of
being covered by the 4CMenB vaccine, but is limited by the requirement
for viable isolates from culture-confirmed cases. We examined if antigen
genotyping could complement MATS in predicting strain coverage by the
4CMenB vaccine.
Methods: From a panel of 3912 MATS-typed invasive meningococcal disease
isolates collected in England and Wales in 2007-2008, 2014-2015 and
2015-2016, and in 16 other countries in 2000-2015, 3481 isolates were
also characterized by antigen genotyping. Individual associations
between antigen genotypes and MATS coverage for each 4CMenB component
were used to define a genetic MATS (gMATS). gMATS estimates were
compared with England and Wales human complement serum bactericidal
assay (hSBA) data and vaccine effectiveness (VE) data from England.
Results: Overall, 81% of the strain panel had genetically predictable
MATS coverage, with 92% accuracy and highly concordant results across
national panels (Lin’s accuracy coefficient, 0.98; root-mean square
deviation, 6%). England and Wales strain coverage estimates were
72-73% by genotyping (66-73% by MATS), underestimating hSBA values
after four vaccine doses (88%) and VE after two doses (83%). The gMATS
predicted strain coverage in other countries was 58-88%.
Conclusions: gMATS can replace MATS in predicting 4CMenB strain coverage
in four out of five cases, without requiring a cultivable isolate, and
is open to further improvement. Both methods underestimated VE in
England. Strain coverage predictions in other countries matched or
exceeded England and Wales estimates. (C) 2019 GlaxoSmithKline
Biologicals SA. Published by Elsevier Ltd."
}